According to the WallStreet Journal, Google, Inc.(NASDAQ:GOOG) is looking to court third-party developers to help it bring customization to smartphone hardware through its Project Ara. The company’s Ara smartphone is based on a metal frame Google designed, and hardware “modules” built by developers will slot into the frame. Analysts have a consensus price target of $675 on Google, Inc.(NASDAQ:GOOGL) which indicates a 24.85% upside. The consensus rating of the stock is a BUY with a score of 2.75. There are currently 1 Hold Rating and 3 Buy ratings on the stock. The most recent analyst action consisted of upgrading the stock from…
Author: Martin Flores
Embattled Canadian smartphone maker BlackBerry Ltd(NASDAQ:BBRY) on Tuesday announced an investment in healthcare IT entity NantHealth, run by billionaire Patrick Soon-Shiong. A statement said details of the intended collaboration are being developed, but both companies said they see “significant opportunities.” The statement said the companies intend to collaborate on the development of HIPAA and other government privacy certified, integrated clinical systems that transform the delivery of medical care. NantHealth is a cloud-based medical IT provider engaged in the delivery of healthcare for payers, providers and patients through real-time connectivity, high performance computing and 21st century decision support. Analysts have a consensus…
Google Inc (NASDAQ:GOOG) announced a deal to acquire drone-maker Titan Aerospace for an undisclosed amount, reports The Wall Street Journal. The Journal said that earlier this year Facebook (NASDAQ:FB) was in talks to acquire Titan, but the social network opted to acquire a different aerospace company, Ascenta. Analysts have a consensus price target of $675 on Google, Inc.(NASDAQ:GOOGL) which indicates a 24.85% upside. The consensus rating of the stock is a BUY with a score of 2.75. There are currently 1 Hold Rating and 3 Buy ratings on the stock. The most recent analyst action consisted of upgrading the stock from…
UniPixel Inc(NASDAQ:UNXL) has promoted Robert Rusenko from vice president of manufacturing to chief operating officer, according to theflyonthewall.com. Before joining UniPixel in April of 2013, Rusenko served as vice president and general manager of Alpharetta printed products at Scientific Games, a global leader in gaming solutions for lottery and gaming organizations. Analysts have a consensus price target of $42 on UniPixel Inc (NASDAQ:UNXL) which indicates a 485% upside. The consensus rating of the stock is a HOLD with a score of 2.17. There are currently 1 Sell Rating, 2 Buy ratings and 1 Sell rating on the stock. A recent analyst…
Intel Corporation (NASDAQ:INTC) shares rose on Tuesday after it announced changes to its financial reporting structure, adding a new Internet of Things Group, which includes its Wind River and McAfee software units. Shares in the chip maker were last at $26.89, up 1.5%, within the 52-week range of $20.80 to $27.12. The changes will take effect beginning with the publication of Intel’s Q1 earnings report on Tuesday, April 15. The company said the changes will better reflect changes in their organizational model, which is aligned with their critical objectives. The PC Client Group will now include the results of the firm’s…
Shares of Amazon.com, Inc. (NASDAQ:AMZN) are back down to the $315 area, near the lows of Friday’s session before the stock then took a bounce. We might see the same effect today if the probe of those lows is successful. That is, if $315 isn’t broken substantially to the downside. If it is, a test to $300 becomes a prospect. On a bounce, resistance is at $322.79. Analysts have a consensus price target of $415.41 on Amazon.com (NASDAQ:AMZN) which indicates a 28.61% upside. The consensus rating of the stock is a BUY with a score of 2.73. There are currently 6…
Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares were down about 5% in pre-market trade on Friday after it priced an underwritten public offering of 2,857,143 shares of its common stock to institutional and other investors at $3.50 per share. In connection with the offering, Cyclacel has granted the underwriters a 30-day option to purchase up to an additional 428,571 shares of common stock to cover over-allotments, if any. All of the shares of common stock in this offering are to be sold by Cyclacel. Cyclacel expects to receive gross proceeds of approximately $10 million from this offering, excluding the underwriters’ over-allotment option and…
Early this morning, GlaxoSmithKline (GSK $53.91) reported negative top-line results from its Phase III MARGIT trial with the MAGE-A3 vaccine in non-small-cell lung cancer. Agenus’s QS-21 adjuvant is a central component of the vaccine and is being studied in 18 other investigational vaccines through a partnership with GlaxoSmithKline. The Phase III trial was designed to assess disease-free survival in GlaxoSmithKline’s MAGE-A3 vaccine versus placebo in roughly 2,270 Stage Ib, II, and IIIa non-small-cell lung cancer patients. Recall that the MAGE-A3 vaccine contains Agenus’ QS-21 adjuvant. While not meeting two of the coprimary endpoints, no major safety signals have been observed…
Roadrunner announced the acquisition of Unitrans International, an international freight forwarder with a focus on cold chain solutions and other complex shipments. In our view, the deal is consistent with the company’s strategy to expand and strengthen its platform by acquiring asset-light transportation providers. In particular, we believe this deal fits well with last year’s acquisition of Marisol as it builds out a more complete offering of value-added international shipping solutions. This is the second acquisition the company has closed so far this year (see our note from February 25, 2014), and we are encouraged that the pipeline remains robust.…
On Thursday morning, Charles River announced the acquisition of Galapagos NV’s CRO services businesses: Argenta and BioFocus. These are European-based CROs focused on discovery services, including medicinal chemistry and other in-vitro solutions. The deal significantly expands Charles River’s presence in discovery services in terms of overall size and scope. This is consistent with management’s strategy to expand further into discovery services, where it sees a favorable demand environment and opportunity to solidify a leadership position. The acquisition is expected to add $0.10 to non-GAAP EPS (excluding the impact of deal cost and amortization of intangible items) in 2014, after the…
We recently hosted investor meetings with TreeHouse’s Chairman and Chief Executive Officer Sam Reed and Chief Financial Officer Dennis Riordan. Management reiterated the fundamental drivers discussed on the company’s fourth-quarter conference call in February. That is, the value equation for consumers, profit and differentiation objectives of retailers, and product and service capabilities of manufacturers point to long-term market share gains for private label in food and beverage. In addition, fragmentation at the manufacturer level—coupled with strategic sourcing by retailers—should drive further consolidation at the manufacturer level. Management sounded optimistic that this backdrop provides the underpinning for modest but stable internal…
Coloplast reported fiscal first-quarter performance that was largely consistent with Street expectations. Coloplast racked up another quarter of solid midsingle-digit top-line growth (in constant currency) and was helped along with a foreign currency tailwind that is expected to reverse over the coming quarters. Both the ostomy and continencecare segments continued to outpace the market at 5% and 7%, respectively. Most of the strength came from the U.K., the U.S., and the Nordic region, which offset weakness in southern Europe. In particular, we are reassured to see ostomy products gaining strength in the U.S. (with revenue growing in the 10% to…